EP HIV-1090

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

CompletedNCT00052182

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2002-10-31Updated: 2007-10-23

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

CompletedNCT00054860

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2005-09-30Target: 42Updated: 2021-10-14

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

CompletedNCT00141024

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2006-01-31End: 2007-12-31Updated: 2021-10-14